Compugen (NASDAQ:CGEN) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Compugen Ltd. (NASDAQ:CGEN)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.30 and traded as high as $2.77. Compugen shares last traded at $2.62, with a volume of 447,159 shares changing hands.

Wall Street Analyst Weigh In

CGEN has been the topic of a number of research reports. Wall Street Zen cut Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. HC Wainwright reaffirmed a “buy” rating on shares of Compugen in a report on Tuesday, August 4th. Leerink Partners decreased their target price on Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, May 21st. Finally, Weiss Ratings raised Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Compugen presently has an average rating of “Buy” and an average target price of $5.00.

Compugen Stock Performance

The stock has a market capitalization of $247.72 million, a price-to-earnings ratio of 6.89 and a beta of 2.77. The company has a 50-day moving average of $2.29 and a 200-day moving average of $2.30.

Compugen (NASDAQ:CGEN) last announced its earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $1.28 million. Compugen had a return on equity of 42.57% and a net margin of 47.56%.During the same quarter in the prior year, the firm earned ($0.08) EPS. As a group, analysts expect that Compugen Ltd. will post -0.27 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CGEN. Bank Hapoalim BM purchased a new stake in shares of Compugen during the fourth quarter worth about $37,000. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Compugen during the fourth quarter valued at approximately $38,000. Franklin Resources Inc. purchased a new position in shares of Compugen during the second quarter valued at approximately $56,000. Calamos Advisors LLC acquired a new stake in Compugen during the first quarter worth approximately $63,000. Finally, Hillsdale Investment Management Inc. acquired a new stake in Compugen during the first quarter worth approximately $68,000. 12.22% of the stock is currently owned by hedge funds and other institutional investors.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.